313 related articles for article (PubMed ID: 28804849)
1. Ristocetin-Induced Platelet Aggregation (RIPA) and RIPA Mixing Studies.
Frontroth JP; Favaloro EJ
Methods Mol Biol; 2017; 1646():473-494. PubMed ID: 28804849
[TBL] [Abstract][Full Text] [Related]
2. Prospective study of low-dose ristocetin-induced platelet aggregation to identify type 2B von Willebrand disease (VWD) and platelet-type VWD in children.
Frontroth JP; Hepner M; Sciuccati G; Feliú Torres A; Pieroni G; Bonduel M
Thromb Haemost; 2010 Dec; 104(6):1158-65. PubMed ID: 20941465
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination.
Stufano F; Baronciani L; Pagliari MT; Franchi F; Cozzi G; Garcia-Oya I; Bucciarelli P; Boscarino M; Peyvandi F
J Thromb Haemost; 2015 Oct; 13(10):1806-14. PubMed ID: 26206100
[TBL] [Abstract][Full Text] [Related]
4. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.
Casonato A; Sartorello F; Pontara E; Gallinaro L; Bertomoro A; Grazia Cattini M; Daidone V; Szukowska M; Pagnan A
Thromb Haemost; 2007 Dec; 98(6):1182-7. PubMed ID: 18064311
[TBL] [Abstract][Full Text] [Related]
5. A new von Willebrand variant (type I, New York): increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing the full range of multimers.
Weiss HJ; Sussman II
Blood; 1986 Jul; 68(1):149-56. PubMed ID: 3487353
[TBL] [Abstract][Full Text] [Related]
6. Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ibalpha in an enzyme-linked immunosorbent assay-based method: performances in patients with type 2B von Willebrand disease.
Caron C; Hilbert L; Vanhoorelbeke K; Deckmyn H; Goudemand J; Mazurier C
Br J Haematol; 2006 Jun; 133(6):655-63. PubMed ID: 16704443
[TBL] [Abstract][Full Text] [Related]
7. Whole blood ristocetin-induced platelet impedance aggregometry does not reflect clinical severity in patients with type 1 von Willebrand disease.
Nakajima Y; Nogami K; Yada K; Ogiwara K; Furukawa S; Shimonishi N; Shima M
Haemophilia; 2019 May; 25(3):e174-e179. PubMed ID: 30866149
[TBL] [Abstract][Full Text] [Related]
8. Laboratory Testing for von Willebrand Disease: The Past, Present, and Future State of Play for von Willebrand Factor Assays that Measure Platelet Binding Activity, with or without Ristocetin.
Just S
Semin Thromb Hemost; 2017 Feb; 43(1):75-91. PubMed ID: 27978590
[TBL] [Abstract][Full Text] [Related]
9. Laboratory Testing for von Willebrand Factor Ristocetin Cofactor (VWF:RCo).
Mohammed S; Favaloro EJ
Methods Mol Biol; 2017; 1646():435-451. PubMed ID: 28804846
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel 14-3-3zeta binding site within the cytoplasmic domain of platelet glycoprotein Ibalpha that plays a key role in regulating the von Willebrand factor binding function of glycoprotein Ib-IX.
Yuan Y; Zhang W; Yan R; Liao Y; Zhao L; Ruan C; Du X; Dai K
Circ Res; 2009 Dec; 105(12):1177-85. PubMed ID: 19875727
[TBL] [Abstract][Full Text] [Related]
11. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.
Giannini S; Mezzasoma AM; Leone M; Gresele P
Haematologica; 2007 Dec; 92(12):1647-54. PubMed ID: 18055988
[TBL] [Abstract][Full Text] [Related]
12. Comparison of different assays for von Willebrand factor in hemodialysis patients.
Borawski J; Pawlak K; Myśliwiec M
Haemostasis; 2000; 30(6):308-15. PubMed ID: 11356999
[TBL] [Abstract][Full Text] [Related]
13. Whole blood ristocetin-activated platelet impedance aggregometry (Multiplate) for the rapid detection of Von Willebrand disease.
Schmidt DE; Bruzelius M; Majeed A; Odeberg J; Holmström M; Ågren A
Thromb Haemost; 2017 Jul; 117(8):1528-1533. PubMed ID: 28692107
[TBL] [Abstract][Full Text] [Related]
14. A sensitive ristocetin co-factor activity assay with recombinant glycoprotein Ibalpha for the diagnosis of patients with low von Willebrand factor levels.
Federici AB; Canciani MT; Forza I; Mannucci PM; Marchese P; Ware J; Ruggeri ZM
Haematologica; 2004 Jan; 89(1):77-85. PubMed ID: 14754609
[TBL] [Abstract][Full Text] [Related]
15. Von Willebrand's disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor.
Grainick HR; Williams SB; McKeown LP; Rick ME; Maisonneuve P; Jenneau C; Sultan Y
J Clin Invest; 1985 Oct; 76(4):1522-9. PubMed ID: 2932469
[TBL] [Abstract][Full Text] [Related]
16. A first Taiwanese Chinese family of type 2B von Willebrand disease with R1306W mutation.
Shen MC; Lin JS; Lin DS; Hsu SC; Lin B
Thromb Res; 2003; 112(5-6):291-5. PubMed ID: 15041272
[TBL] [Abstract][Full Text] [Related]
17. Abnormalities of factor VIII and platelet aggregation--use of ristocetin in diagnosing the von Willebrand syndrome.
Weiss HJ
Blood; 1975 Mar; 45(3):403-12. PubMed ID: 1078779
[TBL] [Abstract][Full Text] [Related]
18. Platelet-type von Willebrand disease: a rare, often misdiagnosed and underdiagnosed bleeding disorder.
Othman M
Semin Thromb Hemost; 2011 Jul; 37(5):464-9. PubMed ID: 22102188
[TBL] [Abstract][Full Text] [Related]
19. Type 2B von Willebrand Disease: A Matter of Plasma Plus Platelet Abnormality.
Castaman G; Federici AB
Semin Thromb Hemost; 2016 Jul; 42(5):478-82. PubMed ID: 27148840
[TBL] [Abstract][Full Text] [Related]
20. The glycoprotein Ibalpha-von Willebrand factor interaction induces platelet apoptosis.
Li S; Wang Z; Liao Y; Zhang W; Shi Q; Yan R; Ruan C; Dai K
J Thromb Haemost; 2010 Feb; 8(2):341-50. PubMed ID: 19840363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
